Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in Il-10-deficient mice

Inflammatory Bowel Diseases

Volumn 14, Issue 11, 2008, Pages 1483-1490

  Ichikawa, Hitoshi ^a   Okamoto, Susumu ^a   Kamada, Nobuhiko ^a   Nagamoto, Hisashi ^b   Kitazume, Mina T ^a   Kobayashi, Taku ^a   Chinen, Hiroshi ^c   Hisamatsu, Tadakazu ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Monocyte; PDE4 inhibitor; Tetomilast

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT3 PROTEIN; SYNAPTOTAGMIN I; TETOMILAST; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC INFLAMMATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL SURVIVAL; CHRONIC DISEASE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROBABILITY; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; CHRONIC DISEASE; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; PROBABILITY; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THIAZOLES;

EID: 59249100809     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20524     Document Type: Article

References (47)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
2. Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol. 2006;41:10-16.
3. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut. 1992;33:773-778.
4. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996;16:144-150.
5. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mono-nuclear cells. Gastroenterology. 1997;112:1169-1178.
6. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
7. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
8. Kamada N, Hisamatsu T, Okamoto S, et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol. 2005;175:6900-6908.
9. Pull SL, Doherty JM, Mills JC, et al. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A. 2005;102: 99-104.
10. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004;5:800-808.
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
12. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
13. Gavalas E, Kountouras J, Stergiopoulos C, et al. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology. 2007;54:1074-1079.
14. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069-2079.
15. van Deventer SJ. New biological therapies in inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2003;17:119-130.
16. Hibi T, Inoue N, Ogata H, et al. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol. 2003;38(suppl 15):36-42.
17. Chihiro M, Nagamoto H, Takemura I, et al. Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. J Med Chem. 1995;38:353-358.
18. Yamamoto KK, Gonzalez GA, Biggs WH 3rd, et al. Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature. 1988;334:494-498.
19. Teixeira MM, Gristwood RW, Cooper N, et al. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci. 1997;18:164-171.
20. Martina SD, Ismail MS, Vesta KS. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann Pharmacother. 2006;40:1822-1828.
21. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:154-161.
22. Hartmann G, Bidlingmaier C, Siegmund B, et al. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther. 2000;292:22-30.
23. Diaz-Granados N, Howe K, Lu J, et al. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol. 2000; 156:2169-2177.
24. Videla S. Selective inhibition of phosphoodiesterase type IV ameliorates chronic colitis and prevents intestinal fibrosis. Gastroenterology. 1998; 114:G4542.
25. Hasegawa T, Sakurai K, Kambayashi Y, et al. Effects of OPC-6535 on lipopolysaccharide-induced acute liver injury in the rat: involvement of superoxide and tumor necrosis factor-alpha from hepatic macrophages. Surgery. 2003;134:818-826.
26. Saverymuttu SH, Camilleri M, Rees H, et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology. 1986;90: 1121-1128.
27. Procopio DO, Teixeira MM, Camargo MM, et al. Differential inhibitory mechanism of cyclic AMP on TNF-alpha and IL-12 synthesis by macrophages exposed to microbial stimuli. Br J Pharmacol. 1999;127:1195-1205.
28. Shames BD, McIntyre RC Jr, Bensard DD, et al. Suppression of tumor necrosis factor alpha production by cAMP in human monocytes: dissociation with mRNA level and independent of interleukin-10. J Surg Res. 2001;99:187-193.
29. Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci. 2004; 25:430-436.
30. Kambayashi T, Jacob CO, Zhou D, et al. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxinstimulated macrophages. J Immunol. 1995;155:4909-4916.
31. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol. 2002;20:55-72.
32. Chi H, Barry SP, Roth RJ, et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A. 2006;103:2274-2279.
33. Hibi T, Ogata H, Sakuraba A. Animal models of inflammatory bowel disease. J Gastroenterol. 2002;37:409-417.
34. Hwang TL, Yeh SH, Leu YL, et al. Inhibition of superoxide anion and elastase release in human neutrophils by 3′-isopropoxychalcone via a cAMP-dependent pathway. Br J Pharmacol. 2006;148:78-87.
35. Prehn JL, Landers C, Muller GW, et al. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol. 2001;21:357-364.
36. Essayan DM. Cyclic nucleotide-phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol. 1999;57:965-973.
37. MacKenzie SJ. Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics. Allergol Int. 2004;53: 101-110.
38. Feng W, Wang Y, Zhang J, et al. Effects of CTx and 8-bromo-cAMP on LPS-induced gene expression of cytokines in murine peritoneal macrophages. Biochem Biophys Res Commun. 2000;269:570-573.
39. Grant V, King AE, Faccenda E, et al. PGE/cAMP and GM-CSF synergise to induce a pro-tolerance cytokine pro.le in monocytic cell lines. Biochem Biophys Res Commun. 2005;331:187-193.
40. Seldon PM, Barnes PJ, Giembycz MA. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes. Cell Biochem Biophys. 1998;29:179-201.
41. Jacob C, Szilagyi C, Allen JM, et al. Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism. Br J Pharmacol. 2004;143:257-268.
42. Staples KJ, Bergmann M, Tomita K, et al. Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol. 2001;167:2074-2080.
43. Bryce PJ, Dascombe MJ, Hutchinson IV. Immunomodulatory effects of pharmacological elevation of cyclic AMP in T lymphocytes proceed via a protein kinase A independent mechanism. Immunopharmacology. 1999;41:139-146.
44. Kang BH, Jo I, Eun SY, et al. Cyclic AMP-dependent protein kinase A and CREB are involved in neuregulin-induced synapse-specific expression of acetylcholine receptor gene. Biochem Biophys Res Commun. 2003;304:758-765.
45. Videla S, Vilaseca J, Medina C, et al. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. J Pharmacol Exp Ther. 2006;316:940-945.
46. Sanz MJ, Cortijo J, Taha MA, et al. Roflumilast inhibits leukocyteendothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol. 2007;152:481-492.
47. Schreiber S, Keshavarzian A, Isaacs KL, et al. A randomized, placebocontrolled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology. 2007;132:76-86.